y of age. Now that the long-term survival rate has increased to 70%, attention focuses on the refinement of treatment to decrease late sequelae in children. A number of late effects have been well documented including cardiotoxicity (2), dysfunction of liver (3), disorders in growth and puberty (4-6), second neoplasms (7), and emotional and neuropsychologic problems (8, 9) . The adverse effects on weight gain in children treated for ALL is, however, less well documented. Obesity is not only a serious somatic problem, but it also affects the psychosocial adaptation of both long-term survivors (10) and their parents (11).
In a study on the late psychosocial effects of surviving childhood ALL (ll), we observed a large proportion of obese patients. Others have confirmed that many survivors are overweight or obese (12) (13) (14) . Obesity seems to be more pro-nounced in girls (13) . Furthermore, excessive weight gain has been observed especially during the first year after the cessation of anti-leukemic therapy (12) . Most studies explain weight gain by cranial irradiation (12) (13) (14) ; however, others suggest that corticosteroid medication might be an important factor in the development of obesity (15) (16) .
We explored the weight of children treated for ALL up to 10 y after cessation of treatment with or without cranial irradiation and with different modes of corticosteroid medication. The early and late effects of these treatment modalities on weight will be evaluated.
METHODS

Subjects.
Patients diagnosed with ALL between 1978 and 1990 at the Sophia Children's Hospital Rotterdam were the subjects of this study. Inclusion criteria for the long-term analysis of obesity were 1) complete first remission for at least 2 y after cessation of treatment and 2) no signs of CNS disease or constitutional chromosomal abnormality. For patients who relapsed after 2 y off therapy (n = 3), data collected only up to 1 y before the date of relapse were included. For patients who were treated with growth hormone therapy (n = 4), respectively 5 (n = I), 6 (n = I), and 7 y (n = 2) after cessation of treatment, only data up to 1 y before the date of endocrine OBESITY AFTER ACUTE LYMPHOBLASTIC LEUKEMIA 87 therapy were included. All eligible patients (n = 113) were enrolled in the study. The sample consisted of 58 boys and 55 girls, median age at diagnosis 3 y, 10 mo (range: 6 mo to 15 y, 0 mo).
Patients were categorized into six groups according to treatment protocol: group 1, HR76; group 2, IIIB; group 3, V; group 4, VI pilot (VIP); group 5, VI; group 6, VII. Patients in group 1 had ALL with initial HR factors, defined as an initial white blood cell count 2 5 0 -1 0~1~ and/or presence of mediastinal mass. Patients in groups 2-5 were diagnosed as NHR-ALL. The treatment for groups 1-5 had the same basic design of induction, followed by CNS treatment and maintenance therapy. Induction consisted of vincristine, corticosteroid, and (except in group 2) L-asparaginase. Children in group 3 were randomized for the addition of daunorubicin (17). In groups 1-3 CNS treatment consisted of 25-Gy cranial irradiation in 13 fractions plus 5 intrathecal injections of MTX delivered in 3 wk. In addition, children in group 1 received intrathecal MTX plus prednisolone once every 7 wk for 1 y (18). Children in groups 4 and 5 received three 24-h i.v. infusions of MDMTX in combination with intrathecal MTX and subsequently intrathecal triple therapy (MTX, cytarabine, prednisolone) once every 7 wk for 1 y (19). Maintenance treatment consisted of 5 wk of daily 6-MP and weekly MTX, alternating with 2 wk of corticosteroid therapy and weekly vincristine. Children in group 2 received only 6-MP and MTX as maintenance. Corticosteroids were prednisone for the children in groups 1-4 or dexamethasone for those in group 5 (19). Total duration of chemotherapy was 3.25 y for group 1 and 2.25 y for groups 2-5. Children in group 6 had HR or NHR-ALL. They were treated with a BFM-86-like protocol with, among others, MDMTX infusions as CNS treatment. No cranial irradiation was given. Prednisone was given during induction; dexamethasone during consolidation (20). Total duration of therapy for group 6 was 1.5 y. Protocols IIIB, V, VIP, VI, and VII were designed by the Dutch Childhood Leukemia Study Group. All protocols are summarized in Tables 1 and 2 .
Measures. Height and weight of patients were repeatedly measured by experienced staff. Data at diagnosis, cessation of treatment, and 1-y intervals thereafter up to 10 y after cessation of treatment were used for this study. BMI was used as an index of obesity according to the formula weight/height2 Data analyses. To obtain estimates of early and late effects of treatment regimens on weight, values at time of diagnosis, cessation of treatment, and 4 y later were evaluated. This latter time point, 5.5-7.25 y from diagnosis, was chosen because all treatment groups had a sufficient number of patients. To compare the mean BMI-SDS at cessation of treatment and 4 y later between the six treatment protocols, analyses of variance were used, F tests ( p < 0.05). The same method of analysis was used to evaluate differences in weight between the separate components of treatment protocols, between both sexes, and different ages at diagnosis. To investigate if mean BMI-SDS differed significantly from zero, t tests, one-tailed (p < 0.05) were applied. To establish the proportion of children with obesity, all children having BMI-SDS greater than 1.28 (above the 90th percentile) were considered as obese.
RESULTS
There was considerable variability in weight scores among individual patients at each time point (Table 3) . Between the six treatment protocols no statistical differences in mean BMI-SDS were found at cessation of treatment (F = 1.83, df = 5, p = 0.11) or 4 y later (F = 0.76, df = 5, p = 0.058). The prevalence of obesity at cessation of treatment and 4 y later for the different treatment protocols indicate that a considerable proportion of survivors are overweight (Table 3) . Children receiving treatment regimens that caused overweight 4 y off therapy (Table 3 : groups 1, 3, and 5) remained overweight thereafter (Fig. 1) . For those protocols which could be evaluated up to 9 or 10 y after cessation of treatment (groups 1-3), weights for children treated with cranial irradiation remained relatively stable (Fig. 1) . Whereas weight gain in groups 1 and 2 remained clearly elevated; in group 3 weight gain remained moderate.
At diagnosis, in all treatment groups mean BMI-SDS were below the mean of the normal population ( Fig. 1; Table 3 ). Of these groups, children in groups 1, 4, 5, and 6 had weights that were significantly below zero. At cessation of treatment all treatment groups had gained weight. Patients in groups 1, 3, and 5 had significantly higher mean BMI-SDS than the reference group, showing a prevalence of obesity of, respectively, 38, 32, and 43%. At this time point most obese children were found in group 5, which included 35 wk of dexamethasone medication without cranial irradiation. Treatment used in group 2 (5 wk of prednisone medication with cranial irradiation) was least associated with short-term weight gain. Four years later, 5.25-7 y from diagnosis, all mean BMI-SDS were still above the mean of the reference group. At this time point mean BMI-SDS of children in groups 1, 3, 5, and 6 were significantly above zero. In these treatment groups, respectively, 27, 31, 26, and 44% of the children were obese. Children in group 2 continued to have lowest weight scores. Effect of treatment factors, gender, and age at diagnosis on weight. At cessation of treatment and 4 y later, the effect of cranial irradiation (yes, no), corticosteroid therapy (prednisone orally, dexamethasone, both), cumulative dose of prednisone orally (1,400, 9,800, and 13,720 mg), gender (boys, girls), and age at diagnosis (0-2 y, 2-6 y, 6-12 y, 12-15 y) on BMI-SDS was investigated. Results are summarized in Table 4 .
Cranial irradiation did not have an effect on weight scores at cessation of treatment or 4 y later. Comparison between protocols with the same cumulative dose of prednisone (9800 mg) but with or without cranial irradiation (group 3 versus group 4) showed no difference in mean BMI-SDS at cessation of treatment ( F = 0.000, df = 1, p = 0.99) nor 4 y later ( F = 0.313, df = 1, p = 0.60). With respect to corticosteroid therapy, type of medication did have an effect on weight gain. At cessation of treatment, children who had received dexamethasone were more obese than children who had received prednisone or both corticosteroids. Four years later, the effect of dexamethasone had dissipated compared with that of other types of medication. Differences between the three types of therapy were not significant, although all children remained overweight in comparison to the reference group. At this time point, children enrolled in group 6, treated with a combination of dexamethasone and prednisone without cranial irradiation, were most obese (44%). The effect of cumulative dose was investigated only in children receiving prednisone therapy. A higher cumulative dose of prednisone was associated with higher BMI-SDS. This finding was consistent at cessation of treatment and 4 y later; however, differences did not reach statistical significance.
There were no differences in mean BMI-SDS between boys and girls at diagnosis ( F = 0.000, df = 1, p = 0.94), cessation of treatment, and 4 y later. We investigated if there was a difference in sensitivity of boys or girls for type of therapy. On both time points (F = 1.3, df = 1, p = 0.25 and F = 0.23, t Group 5 and 6 (protocol VI and VII) excluded from analysis. df = 1, p = 0.63) mean BMI-SDS of patients treated with or without cranial irradiation were not significantly different for boys or girls. Although at cessation of treatment 43% of the irradiated boys were obese versus 21% of the girls, this difference had disappeared (27% versus 31%) 4 y later. For prednisone, dexamethasone, and both types of medication, mean BMI-SDS did not significantly differ between boys and girls at cessation of treatment ( F = 1.53, df = 3, p = 0.22) and 4 y later ( F = 0.64, df = 2, p = 0.53), although prevalence of obesity did differ for boys and girls. At cessation of treatment 40% of the boys treated with prednisone were obese versus 19% of the girls. Furthermore, at that time point boys seemed somewhat more sensitive for dexamethasone, resulting in 47% obesity versus 39% for girls. Differences in obesity between boys and girls were smaller 4 y later. Boys and girls were most affected by the combination of prednisone and dexamethasone, causing, respectively, 40 and 50% of these children to be obese. Age at diagnosis did not have a significant effect on mean BMI-SDS at cessation of treatment or 4 y later. After cessation of treatment, 40% of the youngest and oldest children were obese. Four years later, still 38% of the oldest children were overweight.
DISCUSSION
The improved survival of children with ALL has focused attention on the late effects of anti-leukemic therapy. This retrospective study, representing one of the largest single institutional series on weight of patients surviving ALL, clearly showed that obesity is a late effect for children successfully treated for ALL. Weight gain started during treatment and persisted after cessation of treatment. For treatment regimens that caused significant overweight after cessation of treatment and which could be evaluated up to 10 y after cessation of treatment (groups 1, 3, and 5), mean BMI-SDS did not return to normal values. Our study gives insight into factors which may account for an increase in weight.
It has been suggested that cranial irradiation may cause damage to the hypothalamic-pituitary axis, inducing a decrease in growth and lipolysis which may result in obesity (5, 6, (12) (13) (14) . In contrast, our study clearly demonstrated that protocols with cranial irradiation (groups 1, 2, and 3) did not induce more weight gain than those without cranial irradiation (groups 4, 5, and 6). In fact, protocols with the highest prevalence of obesity at cessation of treatment and 4 y later were those with corticosteroids and without irradiation. This finding implies that the use of corticosteroid therapy has more dominant effect on weight gain than irradiation-induced pituitary dysfunction. Previous studies were not able to test the effect of corticosteroids because no or only small numbers of nonirradiated patients were included (12-16). Another complication in evaluating the effect of irradiation is the use of control groups consisting of children treated for other malignancies (13). Although these groups control for the factor irradiation, they do not control for differences in corticosteroid therapy.
Our study showed that corticosteroid therapy, in particular protocols with dexamethasone, was associated with obesity as an early and late side effect. At cessation of treatment, children who received dexamethasone were more obese than children who received dexamethasone in addition to prednisone. This finding is probably explained by the fact that children on both steroids had a lesser total dose of dexamethasone overall. There was a tendency that a higher cumulative dose of prednisone was related to a higher increase in weight. It has been observed that children during induction chemotherapy receiving high doses of corticosteroids gain weight rapidly (15).
